Introduction {#s1}
============

Glioblastoma (GBM) is the most common and lethal among all gliomas. The current standard of care includes surgery followed by concomitant radiation and chemotherapy with the oral DNA-alkylating agent with good penetration into the blood-brain barrier, temozolomide (TMZ). O^6^-methylguanine-DNA methyltransferase (MGMT) repairs the most cytotoxic lesions generated by TMZ, O^6^-methylguanine. Accordingly, increased expression of MGMT is one of the most robust predictors of the TMZ response in malignant glioma cells. The most important mechanism of silencing of the MGMT gene is methylation of its promoter, resulting in the loss of MGMT expression and diminished DNA repair activity. Therefore, the epigenetic silencing of MGMT gene by its promoter methylation has been shown to be a useful predictor of responsiveness of GBM patients to TMZ (Hegi et al., [@B22]).

Because tumor cells that express MGMT are more resistant to TMZ, targeting the MGMT activity can enhance the therapeutic efficiency of TMZ. Recently, a phase III clinical trial examined the effects of dose-dense TMZ as a strategy to deplete MGMT and enhance the outcome in GBM patients (RTOG0525, ASCO 2011). In addition, preclinical studies and clinical trials are investigating whether it is possible to increase the anticancer potency of TMZ by combining it with other pharmacological agents (Goellner et al., [@B20]; Agnihotri et al., [@B1]). In this review, we discuss drugs that modulate the therapeutic efficacy of TMZ via MGMT-dependent or MGMT-independent mechanisms.

MGMT-dependent mechanism
========================

Methylation of the MGMT promoter in GBM patients correlates with increased susceptibility of the tumor to the alkylating agent therapy. Several drugs have been reported to induce methylation of the MGMT promoter, resulting in increased TMZ cytotoxicity.

O6-benzylguanine (O6-BG)
------------------------

O^6^-benzylguanine (O^6^-BG), a low-molecular-weight substrate, can irreversibly inactivate MGMT, by competing with O^6^-methylguanine. *in vitro* (Dolan et al., [@B13]; Bobola et al., [@B5]) and *in vivo* (Friedman et al., [@B17]) studies confirmed the O^6^-BG increases the therapeutic activity of TMZ. Accordingly, a phase II clinical trial revealed limited benefits with high incidence of bone marrow suppression when patients with TMZ-resistant anaplastic gliomas were treated with both O^6^-BG and TMZ. However, it was disappointing that no significant restoration of TMZ sensitivity occurred in patients with TMZ-resistant GBM (Quinn et al., [@B32]). Because of the limited response seen in GBM patients, alternative dosing regimens should be investigated in order to optimize combination treatment with TMZ and O^6^-BG.

Interferon-β
------------

Interferon-β (IFN-β), which belongs to type I IFNs, was first discovered on the basis of its antiviral activities. Subsequently, it was shown to exhibit pleiotropic biological activities including immunomodulatory activity; antiangiogenic activity; and direct antitumor effects, e.g., growth inhibition and apoptosis (Borden et al., [@B7]). IFN-β markedly enhanced sensitivity to TMZ via downregulation of MGMT transcription (Natsume et al., [@B31]; Yoshino et al., [@B41]). The results of the study suggest that compared to TMZ-based chemotherapy plus radiotherapy, chemotherapy with IFN-β and TMZ and concomitant radiotherapy further improve the clinical outcomes of patients with malignant gliomas. A multicenter phase I clinical trial established that therapy with IFN-β and TMZ is safe, well tolerated, and prolongs survival of patients with GBM (Wakabayashi et al., [@B39]). The median survival time (MST) of patients who underwent the IFN-β and TMZ combination therapy was significantly longer (19.9 months) than that of patients treated with TMZ alone (12.7 months). Remarkably, the MST of patients whose tumors had the unmethylated MGMT promoter was prolonged to 17.2 months when receiving TMZ with IFN-β, compared to 12.5 months in patients receiving TMZ alone. Taken together, IFN-β increased the therapeutic efficiency of TMZ in cases of newly diagnosed primary GBM, particularly in patients with the unmethylated MGMT promoter (Motomura et al., [@B30]). A prospective randomized control trial to compare the clinical outcomes of newly diagnosed GBM patients treated with TMZ alone or with TMZ and IFN-β combination therapy is ongoing.

Levetiracetam
-------------

Some antiepileptic drugs (AEDs) have the ability to inhibit histone deacetylase (HDAC) activity. HDAC inhibitors (HDACi) have transcriptional regulatory activity (Strahl and Allis, [@B34]), suggesting that they can influence TMZ efficacy by modulating the expression of MGMT. HDACs are attractive targets in cancer therapy because their inhibition can induce cell differentiation, growth arrest, and apoptosis (Li et al., [@B26]). Levetiracetam (LEV), a relatively new AED, does not directly inhibit HDAC activity *in vitro* at therapeutic concentration (Eyal et al., [@B14]). Instead, LEV increases the transcription of HDAC1 and recruits the HDAC1/mSin3A corepressor complex to the p53-binding site in the MGMT promoter (Bobustuc et al., [@B6]), thus silencing MGMT (Figure [1](#F1){ref-type="fig"}).

![**Levetiracetam increases HDAC1 transcription and recruit HDAC1/mSin3A corepressor, which binds MGMT promoter region intermediated by p53.** This complex of three components inhibits MGMT transcription.](fonc-02-00098-g0001){#F1}

In contrast, LEV increases MGMT transcription in normal astrocytes (Bobustuc et al., [@B6]) and exerts a neuroprotective role through free-radical scavenging activity (Ueda et al., [@B37]). Moreover, LEV reduces the extent of inflammation and neuronal death by inducing the expression of neurotrophic factors and inducible nitric oxide synthase (iNOS) (Cardile et al., [@B8]). All this activities may contribute to the ability of LEV to prevent radiochemotherapy-induced nerve damage.

Taken together, TMZ-induced cytotoxicity in GBM patients who express high levels of MGMT may be enhanced by concomitant administration of LEV with little adverse effects.

MGMT-independent mechanism
==========================

Several aspects of TMZ sensitivity cannot be explained by MGMT promoter methylation status alone. Actually, the majority of TMZ-induced methylation sites are the N^7^ position of guanine (\>70%) and N^3^ position of adenine (9.2%), whereas O^6^ methylation of guanine directly removed by MGMT is the least frequent adduct (5%). N^7^-methylguanine and N^3^-methyladenine are substrates for the base excision repair (BER) system, which consists of multicatalysis reactions by a wide variety of DNA glycosylases, endonucleases, polymerases, and DNA ligases (Figure [2](#F2){ref-type="fig"}).

![**Two pathways of methylated DNA repair.** TMZ generates a spectrum of DNA lesions including O^6^-methylguanine, N^3^-methyladenine, and N^7^-methylguanine. MGMT eliminates directly the methyl group from O^6^-methylguanine, whereas BER pathway includes multistep reaction by DNA glycosylase (APNG or MPG), endonuclease, polymerase, and DNA ligase. DNA glycosylase recognizes and removes the damaged bases. The abasic site is then hydrolyzed by endonuclease, resulting in the incision of the damaged DNA strand. Polymerase inserts a single nucleotide and DNA ligase completes the repair process. PARP, one of the polymerases of BER, catalyzes the transfer of ADP-ribose units from NAD^+^ to target proteins including PARP itself. Therefore, inhibition or hyperactivation of PARP leads to accumulation of broken DNA or NAD^+^ depletion respectively, consequently inducing cell death.](fonc-02-00098-g0002){#F2}

APNG and GATA4
--------------

The BER enzyme, alkylpurine-DNA-N-glycosylase (APNG), which repairs the cytotoxic lesions N\^3-methyladenine and N^7-methylguanine^, contributes to TMZ resistance. Silencing of APNG in TMZ-resistant GBM cell lines that express MGMT and APNG attenuated the repair of TMZ-induced DNA damage and enhanced apoptosis. Accordingly, exogenous expression of APNG in TMZ-sensitive GBM lines conferred resistance to TMZ *in vitro* and *in vivo* (Agnihotri et al., [@B1]), confirming that APNG contributes to TMZ resistance in GBM.

The GATA transcription factor family consists of six members, which bind to a consensus DNA-binding element. Recently, it was reported that GATA4 is expressed in the embryonic and adult central nervous system, inhibits astrocyte proliferation, and acts as a tumor suppressor in GBM (Agnihotri et al., [@B3]). Loss of GATA4, observed in the majority of GBM, was a negative prognostic marker. Re-expression of GATA4 conferred sensitivity of GBM cells to TMZ, which was independent of MGMT (Agnihotri et al., [@B2]). However, GATA4 reduced the expression of APNG, suggesting that GATA4 increases the anticancer potency of TMZ in human GBM cells.

MPG, Polβ, PARP, NAD^+^ biosynthesis
------------------------------------

Overexpression of the BER-initiating enzyme N-methylpurine DNA glycosylase (MPG) greatly enhances the effect of TMZ through the imbalance of DNA repair, independent of the MGMT status (Fishel et al., [@B16]; Goellner et al., [@B20]). Increased MPG activity induced single-strand and double-strand breaks in DNA, leading to apoptotic cell death (Dobson et al., [@B12]). However, these effects were abrogated by elevated expression of the rate-limiting BER enzyme DNA polymerase β (Polβ) (Tang et al., [@B36]). Thus, the expression levels of MPG and Polβ in tumors may represent biomarkers for alkylator therapy.

Poly (ADP-ribose) polymerase (PARP) is involved in DNA repair. PARP1 particularly has the dual effect. The cytotoxic effect of alkylating agents is enhanced by either its inhibition or hyperactivation. Inhibition of PARP1 accumulates broken DNA in the cells, resulting in cell death (Figure [2](#F2){ref-type="fig"}). PARP1 is the primary enzyme catalyzing the transfer of ADP-ribose units from nicotinamide adenine dinucleotide (NAD+) to target proteins including itself. Therefore, PARP1 hyperactivation leads to depletion of NAD^+^ and ATP, which are necessary for cell metabolism, followed by cell death (Tang et al., [@B35]) (Figure [2](#F2){ref-type="fig"}).

Inhibition of NAD^+^ biosynthesis also potentiates alkylator-induced cytotoxicity (Figure [2](#F2){ref-type="fig"}). Therefore, dual inhibition of BER and NAD^+^ biosynthesis might sensitize glioma cells to TMZ, independent of MGMT status (Goellner et al., [@B20]).

Resveratrol
-----------

Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a stilbenoid found in the rinds of red grapes and in other fruits. It exhibits antioxidant, anticancer, cardioprotective, and anti-aging effects, among others. Importantly, resveratrol has been identified as a potential cancer chemopreventive agent based on its ability to modulate cancer initiation, promotion, and progression. Resveratrol increases TMZ efficacy and although the influence of resveratrol on MGMT is unknown, the combination of TMZ and resveratrol has a synergistic effect *in vitro* and *in vivo* (Lin et al., [@B27]). TMZ induces both apoptotic cell death and cytoprotective autophagy through a reactive oxygen species (ROS) burst and extracellular signal-regulated kinase (ERK) activation. Resveratrol possesses antioxidant or pro-oxidant activity (Holme and Pervaiz, [@B23]). It is possible that resveratrol suppresses TMZ-induced ROS/ERK-mediated autophagy, resulting in increased apoptosis. These data indicate that resveratrol may improve the efficacy of TMZ in patients with GBM.

Unknown mechanisms
==================

Valproic ACID
-------------

Valproic acid (VPA) is a commonly prescribed AED for the treatment and prevention of seizures in patients with glioma. In addition to its antiseizure properties, VPA inhibits cell proliferation and induces differentiation and apoptosis in cancer cells (Gottlicher et al., [@B21]; Li et al., [@B26]).

Patients with GBM who were treated with VPA appeared to have a better outcome than did those not treated with VPA or treated with other AEDs (Weller et al., [@B40]). At least four mechanisms underlying the anti-tumor effect of VPA may be considered. First, HDAC inhibition by VPA promotes histone acetylation that loosens up the chromatin structure, consequently increasing DNA accessibility to anticancer drugs such as TMZ and enhancing the effect of γ-radiation (Van Nifterik et al., [@B38]). Second, concurrent treatment with VPA and TMZ synergistically induces apoptosis *in vitro* independent of the p53 status (Chen et al., [@B9]). Third, VPA induces autophagy, which is a caspase-independent process characterized by the accumulation of autophagic vacuoles in the cytoplasm, accompanied by extensive degradation of organelles (Fu et al., [@B19]). VPA sensitizes melanoma cells to TMZ *in vitro* and *in vivo* by activating the apoptotic cascade. This effect is significantly increased by INF-β (Roos et al., [@B33]). Fourth, VPA increases the bioavailability of TMZ by reducing the clearance of the metabolite that methylates DNA ([www.temodar.com](http://www.temodar.com)).

Therefore, VPA may affect the survival of glioma patients via different pathways.

Ribonucleotide reductase inhibitors
-----------------------------------

Biosynthesis of deoxyribonucleotides (dNTP) from ribonucleotides is an essential step in DNA synthesis and cell replication. Ribonucleotide reductase (RR), the rate-limiting enzyme of this pathway, appears to be a negative predictive factor in patients with cancer (Jordheim et al., [@B25]). Several drugs that inhibit RR, such as hydroxyurea, gemcitabine, and fludarabine are used for the treatment of a variety of cancers. Among the RR inhibitors, didox (DX), and trimidox (TX) are the most potent enzyme inhibitors that demonstrated excellent anticancer activity in animal tumor models (Fritzer-Szekeres et al., [@B18]) and enhanced alkylator-induced cytotoxicity *in vitro* (Horvath et al., [@B24]). Depletion or imbalance of dNTPs by RR inhibitors may potentiate TMZ-induced cytotoxicity independent of the p53 status (Figul et al., [@B15]). Since most gliomas have a defective p53-mediated pathway, the ability of RR inhibitors to induce apoptosis in a p53-independent manner is an asset (Dehais et al., [@B11]; Masica and Karchin, [@B28]). In addition, RR inhibitors may enhance the radiosensitivity of the tumor by inducing G1/S arrest and/or by inhibiting DNA repair (Barker et al., [@B4]; Zuckerman et al., [@B42]). Inhibition of DNA synthesis by RR inhibitors may increase the time available for DNA repair in response to TMZ-mediated damage.

In addition to synergistic cytotoxicity, DX and TX can decrease the optimal dose of TMZ (Figul et al., [@B15]), thereby reducing potential adverse effects, such as myelosuppression.

Prospective
===========

Recent investigations have increased the understanding of the pharmacological mechanisms of TMZ. It is likely that drugs and mechanisms other than those discussed above modulate TMZ efficacy. One such mechanism is the inhibition of GSK3β, which is a serine/threonine kinase that is overexpressed and activated in GBM. We have previously reported that GSK3β inhibitor sensitized GBM cells to TMZ-induced apoptosis *in vitro* via an unknown mechanism (Miyashita et al., [@B29]). Notably, VPA has been shown to inhibit the activity of GSK3β (Chen et al., [@B10]), suggesting that GSK3β inhibition is one of the mechanisms by which VPA enhances the therapeutic efficiency of TMZ.

At present, TMZ plays a central role in the treatment of GBM. Future studies on the drugs that enhance TMZ activity without side effects are warranted, as adjuncts to standard chemotherapies can improve therapeutic benefit and prolong survival.
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